ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
NASDAQ:EPIX
Price:
6.88 USD
-1.01%
Market Closed
Updated:
May 6, 2024
ESSA Pharma Inc
Cash from Financing Activities
|
ESSA Pharma Inc
Cash from Financing Activities Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Cash from Financing Activities
$108.5k
|
CAGR 3-Years
-87%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
See Also
What is ESSA Pharma Inc's Cash from Financing Activities?
Cash from Financing Activities
108.5k
USD
108.5k
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Cash from Financing Activities amounts to 108.5k USD.
What is ESSA Pharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-65%
-65%
Over the last year, the Cash from Financing Activities growth was -36%. The average annual Cash from Financing Activities growth rates for ESSA Pharma Inc have been -87% over the past three years , -65% over the past five years .
You don't have any saved screeners yet
